Annovis Bio Inc (ANVS)
NYSEHealth CareBiotechnologySnapshot 2026-09-04
$1.39+0.72%
Close 2026-09-04 · 1-day change
NYSEHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ANVS
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | |
|---|---|---|---|---|---|---|---|
| Revenues | |||||||
| Revenues | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating Expenses & Income | |||||||
| R&D Expenses | 43.8 | 25.2 | 20.0 | 38.8 | 16.5 | 8.5 | 3.1 |
| Operating Income | (49.5) | (29.7) | (26.7) | (45.0) | (25.5) | (14.5) | (6.6) |
| Earnings from Continuing Operations | |||||||
| Interest & Investment Income | 0.6 | 0.7 | 0.3 | 0.7 | — | — | — |
| Other Non-Operating Income / Expenses | 0.0 | 0.8 | 2.1 | (11.2) | 0.2 | 0.1 | 1.2 |
| EBT, Incl. Unusual Items | — | — | — | (56.2) | (25.3) | (14.5) | (5.5) |
| Income Tax Expense | 0.0 | — | — | — | — | — | — |
| Net Income | |||||||
| Net Income | (49.5) | (28.9) | (24.6) | (56.2) | (25.3) | (14.5) | (5.5) |
| Per Share | |||||||
| Basic EPS | (1.32) | (1.40) | (2.02) | (6.23) | (3.10) | (1.90) | (0.87) |
| Diluted EPS | (1.32) | (1.40) | (2.31) | (6.23) | (3.10) | (1.90) | (0.87) |
| Basic Weighted Avg Shares | 37.5 | 20.6 | 12.2 | 9.0 | 8.2 | 7.6 | 6.3 |
| Diluted Weighted Avg Shares | 37.5 | 20.6 | 12.2 | 9.0 | 8.2 | 7.6 | 6.3 |
| Supplemental | |||||||
| EBIT | (49.5) | (29.7) | (26.7) | (45.0) | (25.5) | (14.5) | (6.6) |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.